Search Results - "Massimiliano, Petrini"
-
1
The Renewal of Cancer Immunotherapy
Published in Vaccines (Basel) (01-03-2023)“…Cancer immunotherapy embraces many current, promising therapeutic approaches to eradicate tumors by activating host antitumor activity [...]…”
Get full text
Journal Article -
2
Potency Assessment of Dendritic Cell Anticancer Vaccine: Validation of the Co-Flow DC Assay
Published in International journal of molecular sciences (29-05-2021)“…For many years, oncological clinical trials have taken advantage of dendritic cells (DC) for the design of DC-based cellular therapies. This has required the…”
Get full text
Journal Article -
3
Dendritic Cell Vaccination in Metastatic Melanoma Turns "Non-T Cell Inflamed" Into "T-Cell Inflamed" Tumors
Published in Frontiers in immunology (09-10-2019)“…Dendritic cell (DC)-based vaccination effectively induces anti-tumor immunity, although in the majority of cases this does not translate into a durable…”
Get full text
Journal Article -
4
First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax)
Published in Frontiers in immunology (13-08-2024)“…Glioblastoma (GBM) is a poor prognosis grade 4 glioma. After surgical resection, the standard therapy consists of concurrent radiotherapy (RT) and temozolomide…”
Get full text
Journal Article -
5
Radiotherapy and High-Dose Interleukin-2: Clinical and Immunological Results of a Proof of Principle Study in Metastatic Melanoma and Renal Cell Carcinoma
Published in Frontiers in immunology (27-10-2021)“…High-dose interleukin-2 (HD IL-2) has curative potential in metastatic melanoma (MM) and renal cell carcinoma (RCC). Radiotherapy (RT) kills cancer cells and…”
Get full text
Journal Article -
6
Stability Program in Dendritic Cell Vaccines: A “Real-World” Experience in the Immuno-Gene Therapy Factory of Romagna Cancer Center
Published in Vaccines (Basel) (23-06-2022)“…Advanced therapy medical products (ATMPs) are rapidly growing as innovative medicines for the treatment of several diseases. Hence, the role of quality…”
Get full text
Journal Article -
7
Evaluation of in vivo labelled dendritic cell migration in cancer patients
Published in Journal of translational medicine (30-07-2004)“…BACKGROUND: Dendritic Cell (DC) vaccination is a very promising therapeutic strategy in cancer patients. The immunizing ability of DC is critically influenced…”
Get full text
Journal Article -
8
Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients
Published in Journal of translational medicine (16-08-2006)“…We present our experience of therapeutic vaccination using dendritic cells (DC) pulsed with autologous tumor antigens in patients with advanced melanoma…”
Get full text
Journal Article -
9
Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis
Published in Clinical & developmental immunology (01-01-2010)“…We reviewed the clinical results of a dendritic cell-based phase II clinical vaccine trial in stage IV melanoma and analyzed a patient subgroup treated with…”
Get full text
Journal Article -
10
FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy
Published in Journal of translational medicine (03-06-2010)“…Antigen processing by dendritic cells (DC) exposed to specific stimuli has been well characterized in biological studies. Nonetheless, the question of whether…”
Get full text
Journal Article -
11
A New Gene Family Including DSCR1 (Down Syndrome Candidate Region 1) and ZAKI-4: Characterization from Yeast to Human and Identification of DSCR1-like 2, a Novel Human Member (DSCR1L2)
Published in Genomics (San Diego, Calif.) (15-03-2000)“…A new gene family has been identified on the basis of in-depth bioinformatics analysis of the Down syndrome candidate region 1 (DSCR1) gene, located on…”
Get full text
Journal Article -
12
Erratum to “Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis”
Published in Clinical & developmental immunology (2011)“…The authors would like to add Dr. LindaValmorriat to the authors' list. Thus, the authors' list will be:Laura Ridolfi, Massimiliano Petrini, Laura Fiammenghi,…”
Get full text
Journal Article -
13
In vitro CAR-T cell killing: validation of the potency assay
Published in Cancer Immunology, Immunotherapy : CII (02-07-2024)“…For advanced therapy medicinal products, the development and validation of potency assays are required, in accordance with international guidelines, to…”
Get full text
Journal Article -
14
Results from the first step of a phase II study of vaccination with autologous dendritic cells loaded with autologous tumour homogenate in glioblastoma
Published in Journal of clinical oncology (01-06-2023)“…e14025 Background: Glioblastoma (GBM) is a poor prognosis malignant grade IV glioma. After surgical resection, standard therapy consists of concomitant…”
Get full text
Journal Article -
15
Dendritic cell vaccines as cancer treatment: focus on 13 years of manufacturing and quality control experience in advanced therapy medicinal products
Published in Cytotherapy (Oxford, England) (01-12-2024)“…Dendritic cells (DCs) are professional antigen-presenting cells of the mammalian immune system. Ex vivo differentiated DCs represent a unique Advanced Therapy…”
Get full text
Journal Article -
16
Skewing effect of sulprostone on dendritic cell maturation compared with dinoprostone
Published in Cytotherapy (Oxford, England) (01-06-2018)“…Abstract Background Dendritic cells (DCs) are the most efficient antigen-presenting cells and act at the center of the immune system owing to their ability to…”
Get full text
Journal Article -
17
Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients
Published in Journal of translational medicine (31-05-2013)“…In cancer immunotherapy, dendritic cells (DCs) play a fundamental role in the dialog between innate and adaptive immune response, but several immunosuppressive…”
Get full text
Journal Article -
18
Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial)
Published in BMJ open (01-08-2018)“…IntroductionSurgery is one of the treatments of choice for patients with a single metastasis from melanoma but is rarely curative. Such patients could…”
Get full text
Journal Article -
19
Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience
Published in Melanoma research (01-08-2017)“…Although immunomodulating antibodies are highly effective in metastatic melanoma, their toxicity, related to the activation of T lymphocytes, can be severe…”
Get full text
Journal Article -
20
Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-α in patients with metastatic melanoma: a randomised "proof-of-principle" phase II study
Published in Journal of translational medicine (22-07-2014)“…Vaccination with dendritic cells (DC) loaded with tumor antigens elicits tumor-specific immune responses capable of killing cancer cells without inducing…”
Get full text
Journal Article